EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease

Katherine R Tuttle, Peter Rossing, Sibylle J Hauske, Lisa Cronin, Joanna Hussain, Dick de Zeeuw, Hiddo J L Heerspink

American Journal of Nephrology · 2024

DOI: 10.1159/000534808 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Katherine R Tuttle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Washington, Spokane, Washington, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucosides, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Aldosterone synthase (AS) inhibition may overcome increased aldosterone production in response to renin-angiotensin system inhibition. BI 690517 is an AS inhibitor under investigation for chronic kidney disease (CKD).

Methods

This multinational, phase II, double-blind study (NCT05182840) investigated the efficacy and safety of daily oral BI 690517, with or without empagliflozin 10 mg, in participants with CKD. The primary endpoint was change from baseline in urine albumin:creatinine ratio (UACR) at week 14. Between February 18, 2022, and December 30, 2022, 714 adults already treated by angiotensin-converting enzyme inhibitor (30.5%) or angiotensin receptor blocker (69.8%) were randomized (1:1) to an 8-week run-in to assign background empagliflozin (n = 356) or placebo (n = 358). Participants in each group were then randomized (1:1:1:1) to a 14-week treatment period with BI 690517 (3 mg, 10 mg, or 20 mg) or placebo. Of the 714 participants who entered run-in, 586 were randomized to the treatment period. They were predominantly men (66.6%) of white race (58.4%) with a mean (standard deviation [SD]) age of 63.8 (11.3) years. Type 2 diabetes was present in 414 participants (70.6%). The baseline mean (SD) estimated glomerular filtration rate was 51.9 (17.7) mL/min/1.73 m2, and median (interquartile range) UACR was 426.3 mg/g (205.3–888.5).

Conclusion

This study will inform dose selection for further clinical development and determine whether BI 690517, with or without background empagliflozin, has a favorable safety profile and potential for additive kidney protection in participants with CKD already treated with a renin-angiotensin system inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GlucosidesRenal Insufficiency, ChronicFemaleHumansMaleMiddle AgedAlbuminuriaBenzhydryl CompoundsCytochrome P-450 CYP11B2Double-Blind MethodGlomerular Filtration RateClinical Trials, Phase II as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

AlbuminuriaChronic kidney diseasePhase II clinical trialRenin-angiotensin-aldosterone systemSodium-glucose cotransporter 2 inhibitor

Substanzen

Benzhydryl CompoundsCytochrome P-450 CYP11B2empagliflozinGlucosides

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, University of Washington, Spokane, Washington, USA.
  • Complications Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Vth Department of Medicine, University Medical Center Mannheim, Heidelberg University, Heidelberg, Germany.
  • Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
  • Boehringer Ingelheim Ltd, Bracknell, UK.

Zitieren

APA

Tuttle, K. R., Rossing, P., Hauske, S. J., Cronin, L., Hussain, J., de Zeeuw, D., & Heerspink, H. J. L. (2024). Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease. American Journal of Nephrology. https://doi.org/10.1159/000534808

Vancouver

Tuttle KR, Rossing P, Hauske SJ, Cronin L, Hussain J, de Zeeuw D, et al. Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease. American Journal of Nephrology. 2024. doi:10.1159/000534808

BibTeX
@article{Tuttle2024,
  author = {Tuttle, Katherine R and Rossing, Peter and Hauske, Sibylle J and Cronin, Lisa and Hussain, Joanna and de Zeeuw, Dick and Heerspink, Hiddo J L},
  title = {Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease},
  journal = {American Journal of Nephrology},
  year = {2024},
  doi = {10.1159/000534808}
}
Kostenlos starten →